Symbol
| CUL1
| contributors: mct/pgu - updated : 20-02-2018
|
HGNC name
| cullin 1
|
HGNC id
| 2551
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
significantly associated with high-grade tumours and poor prognosis | tumoral
|  
|  
| --over
|  
|
in renal cell carcinoma (RCC) | tumoral
|  
|  
| --over
|  
|
in melanoma, enhancing melanoma cell proliferation by promoting G1-S phase transition | tumoral
|  
|  
| --over
|  
|
positively associated with lymph node metastasis and tumor diameter | tumoral
|  
|  
| --over
|  
|
significantly increased in human glioma, and it may be involved in proliferation, migration and invasion of glioma cells | |
Susceptibility
|
may affect the susceptibility of rheumatoid arthritis (RA) via altering lymphocyte signal transduction |
Variant & Polymorphism
other
| possible role of CUL1 variation(s) in RA and its response to methotrexate |
|
|
|
|
Candidate gene
Marker
| its expression may therefore be crucial for the prediction of disease outcome in breast cancer patients | |
CUL1 may be an important prognosis marker for human hepatocellular carcinoma (HCC) | |
may serve as promising prognostic markers in colorectal cancer (CRC) patients | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | urinary | | |
CUL1 may constitute a potential therapeutic target in enal cell carcinoma (RCC) |
| | |
| dysregulation of cyclin E and early embryonic lethality in CUL1-/- | |
cul1-/- sequestrate and inactivate Skp1 leading to genetic instability and neoplastic transformation |